Research on psoriasis pathogenesis has largely increased knowledge on skin biology in
general. In the past 15 years, breakthroughs in the understanding of the pathogenesis of …

Interleukin-23 (IL-23) is a pro-inflammatory cytokine composed of two subunits, IL-23A (p19)
and IL-12/23B (p40), the latter shared with Interleukin-12 (IL-12). IL-23 is mainly produced …

Psoriasis is a chronic, immune-mediated, inflammatory disease that is pathogenically driven
by proinflammatory cytokines. This article reviews the immunologic role of interleukin (IL)-17 …

Autoimmune skin diseases are characterized by significant local and systemic inflammation
that is largely mediated by the Janus kinase (JAK)–signal transducer and activator of …

Dupilumab, an IL-4/IL-13 receptor blocker, has been linked to emergent seronegative
inflammatory arthritis and psoriasis that form part of the spondyloarthropathy spectrum. We …

Over the past several years, a pathophysiological role for the IL-23–IL-17 pathway in human
disease has been defined. A subset of rheumatic diseases, including psoriatic arthritis (PsA) …

Interleukin (IL)-17A has a direct contribution in early induction and late chronic stages of
various inflammatory diseases. In vitro and in vivo experiments have first characterized its …

Psoriasis vulgaris is a chronic, immune-mediated, inflammatory, polygenic skin disorder
affecting approximately 2% of the population. It has a great impact on quality of life; patients …

Interleukin (IL)-17 is a T helper 17 cytokine implicated in the pathogenesis of many
autoimmune diseases, including rheumatoid arthritis (RA). Although IL-17A has a well …

Recent knowledge on the key role of interleukin (IL) 23/17 axis in psoriasis pathogenesis,
led to development of new biologic drugs. Risankizumab is a humanized immunoglobulin …